Cryptococcus neoformans
PharmacologyPharmacodynamics of Isavuconazole in a Rabbit Model of Cryptococcal MeningoencephalitisCryptococcus spp., important fungal pathogens, are the leading cause of fungus-related mortality in human immunodeficiency virus-infected patients, and new therapeutic options are desperately needed. Isavuconazonium sulfate, a newer triazole antifungal agent, was studied to characterize the exposure-response relationship in a rabbit model of cryptococcal meningoencephalitis. Rabbits treated with isavuconazonium sulfate were...
Experimental TherapeuticsIn Vivo Efficacy of VT-1129 against Experimental Cryptococcal Meningitis with the Use of a Loading Dose-Maintenance Dose Administration StrategyVT-1129 is a novel fungal enzyme-specific Cyp51 inhibitor with potent cryptococcal activity. Because of its long half-life (>6 days in mice) and our desire to quickly reach potent efficacy, we evaluated a VT-1129 loading dose-maintenance dose strategy against cryptococcal meningitis.
- Experimental TherapeuticsThe Fungal Cyp51 Inhibitor VT-1129 Is Efficacious in an Experimental Model of Cryptococcal Meningitis
Cryptococcal meningitis is a significant cause of morbidity and mortality in immunocompromised patients. VT-1129 is a novel fungus-specific Cyp51 inhibitor with potent in vitro activity against Cryptococcus species.
- Experimental TherapeuticsAcylhydrazones as Antifungal Agents Targeting the Synthesis of Fungal Sphingolipids
- Experimental TherapeuticsAntimicrobial Octapeptin C4 Analogues Active against Cryptococcus Species
- Experimental TherapeuticsTroponoids Can Inhibit Growth of the Human Fungal Pathogen Cryptococcus neoformans